• Glaukos completed patient enrollment in a Phase 2 trial of GLK-321 for Demodex blepharitis; results have not yet been presented.
• The study will assess whether the investigational eyelid-applied treatment can clear a key sign of the disease over six weeks.
• The trial is designed to support a potential new ocular-surface franchise using the iLution drug-delivery platform, targeting a large, underdiagnosed market.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Glaukos Corporation published the original content used to generate this news brief via Business Wire (Ref. ID: 20260625276927) on June 25, 2026, and is solely responsible for the information contained therein.